BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) announced today that the pivotal Phase 3 study of GALNS met the primary endpoint of ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE